News and Announcements
Additional Placement Raises $1.0 million for Prescient Therapeutics
- Published November 26, 2015 11:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th November 2015, ASX Announcement
Cancer drug development company Prescient Therapeutics Limited (ASX: PTX) (‘Prescient’, ‘PTX’ or ‘the Company’) advises that following the oversubscribed Share Purchase Plan (‘SPP’), the Company has subsequently raised approximately $1.0million. The Company is completing an additional top up placement of approximately 19.3 million fully paid ordinary shares at $0.054 (5.4 cents) per share, which is the same price as the SPP issue price. Together with the recently completed SPP, PTX has raised approximately $2.0 million, exceeding the Company’s expectations.
PTX expects these funds to provide for efforts to achieve multiple milestones across its clinical programs over the next 12 to 18 months.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
